As combination products continue to advance, the industry is moving beyond reliable drug delivery alone—and toward solutions that support patients throughout the entire treatment journey.
A newly announced partnership between Aptar Digital Health and Enable Injections highlights this shift. The collaboration brings together Enable’s enFuse® on-body delivery system with a purpose‑built digital companion solution designed to guide, support, and engage patients before, during, and after injection.
Together, the companies are setting a new standard for how device, therapy, and digital support can work seamlessly to improve the patient experience.
Digital Companions: Extending Value Beyond the Moment of Injection
The enFuse® system is designed to deliver large-volume biologics subcutaneously—often for complex, chronic conditions that require long-term adherence. While innovative delivery devices remove physical and logistical barriers, many patients still face challenges such as injection anxiety, inconsistent technique, and uncertainty between doses.
The digital companion solution being developed by Aptar Digital Health is intended to address these gaps by offering:
- Guided onboarding and training experiences
- Step-by-step injection support
- Treatment data capture and tracking
- Patient‑reported outcomes and symptom monitoring
By supporting patients across the treatment lifecycle—not just at the point of administration—digital solutions like this can help build confidence, promote consistency, and reinforce adherence over time.
Designing for the Full Drug Development Lifecycle
One of the most notable aspects of this partnership is its modular, scalable approach. The digital companion is designed to evolve alongside the therapy, supporting use cases ranging from clinical trials to commercialization.
This flexibility allows pharmaceutical partners to:
- Capture real‑world data earlier in development
- Generate actionable insights through analytics dashboards
- Tailor digital components to specific clinical or commercial programs
As regulatory scrutiny, real‑world evidence expectations, and patient experience benchmarks continue to rise, adaptable digital ecosystems are becoming integral to successful launch and lifecycle strategies.
Why This Matters for the Broader Industry
This collaboration underscores a growing industry truth: patient experience is now a strategic differentiator.
Successful combination products increasingly depend on how well patients are supported at home—especially as more therapies move outside traditional care settings. Digital tools that complement advanced delivery systems can strengthen engagement, empower caregivers, and give healthcare teams deeper visibility into real‑world use.
As Enable Injections’ leadership noted in the announcement, the goal is to enhance the experience beyond the moment of injection—while Aptar Digital Health emphasized the role digital solutions play in addressing adherence challenges common to self‑administration.
Advancing Patient‑Centered Care Through Integrated Solutions
At Noble, we see this partnership as further validation of where the market is headed: integrated ecosystems that combine device innovation, digital engagement, and patient education to improve outcomes.
As therapies grow more complex and patient responsibility increases, solutions that simplify, guide, and reassure patients will be essential—not optional. Collaborations like Aptar Digital Health and Enable Injections’ are an important step toward making at‑home treatment experiences more intuitive, connected, and human‑centered.